The use of real-world data in cancer drug development

Area of Science:

• Oncology
• Health Technology Assessment
• Regulatory Science

Background:

• Anticancer drug development faces challenges with high costs and lengthy regulatory approval processes.
• Translating experimental clinical data into real-world evidence (RWE) for regulatory use remains a significant hurdle.
• Randomized controlled trials (RCTs) are the established standard for assessing drug efficacy and safety.

Purpose of the Study:

• To explore the potential of real-world evidence (RWE) to overcome limitations in anticancer drug development and approval.
• To advocate for the balanced integration of RWE into regulatory and health technology assessment (HTA) processes.
• To facilitate faster and broader access to innovative anticancer therapies.

Main Methods:

• Review of current challenges in anticancer drug development and regulatory pathways.
• Discussion on the role and potential of observational data and RWE.
• Analysis of the benefits of incorporating RWE into decision-making frameworks.

Main Results:

• RWE offers a complementary approach to RCTs for evaluating anticancer medicines.
• Integrating RWE can potentially expedite the availability of novel cancer treatments.
• Thoughtful consideration of RWE can enhance the robustness of regulatory and HTA decisions.

Conclusions:

• Real-world evidence presents a valuable opportunity to improve access to anticancer medicines.
• Balancing RWE with traditional trial data is crucial for informed regulatory and HTA decision-making.
• Strategic use of RWE can accelerate the translation of scientific advancements into clinical practice.